Tags

Type your tag names separated by a space and hit enter

Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome.
Nutr Metab (Lond) 2016; 13:10NM

Abstract

BACKGROUND

The treatment of Irritable bowel syndrome (IBS) is still challenging. Partially hydrolyzed guar gum (PHGG) is a known prebiotic fiber. To assess the effects of PHGG on clinical symptoms of IBS patients in a prospective randomized double blind placebo-controlled study.

METHODS

Suitable IBS patients were recruited into an 18-week-long study (2 weeks of run-in, 12 weeks of treatment and 4 weeks of follow-up). They were blindly randomized to receive 6 gr of PHGG or placebo. Treatment efficacy was evaluated by the Francis Severity IBS score, the IBS quality-of-life scores and scored parameters of weekly journal of symptoms. Deltas of changes between the final and baseline scores were compared between two groups.

RESULTS

Of 121 patients who underwent randomization, 108 patients (49 in the PHGG group and 59 in the placebo group) had all the data needed for intention-to-treat analysis. A 12-week administration of PHGG led to a significant improvement of journal bloating score in the PHGG group versus placebo (-4.1±13.4 versus -1.2±11.9, P=0.03), as well as in bloating+gasses score (-4.3±10.4 versus -1.12±10.5, P = 0.035). The effect lasted for at least 4 weeks after the last PHGG administration. PHGG had no effect on other journal reported IBS symptoms or on Severity and Quality of life scores. There were no significant side effects associated with PHGG ingestion. The rate of dropouts was significantly higher among patients in the placebo group compared with the PHGG group (49.15% versus 22.45%, respectively, P = 0.01).

CONCLUSIONS

The results of this study support the administration of 6 g/day PHGG for IBS patients with bloating.

TRIAL REGISTRATION

NCT01779765.

Authors+Show Affiliations

Unit of Clinical Nutrition, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, 6423906 Israel.The Department of Gastroenterology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.The Department of Gastroenterology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.The Department of Gastroenterology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.The Department of Gastroenterology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.The Department of Gastroenterology, Sapir Medical Center, Kfar-Saba, Israel.Unit of Clinical Nutrition, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, 6423906 Israel.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26855665

Citation

Niv, E, et al. "Randomized Clinical Study: Partially Hydrolyzed Guar Gum (PHGG) Versus Placebo in the Treatment of Patients With Irritable Bowel Syndrome." Nutrition & Metabolism, vol. 13, 2016, p. 10.
Niv E, Halak A, Tiommny E, et al. Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. Nutr Metab (Lond). 2016;13:10.
Niv, E., Halak, A., Tiommny, E., Yanai, H., Strul, H., Naftali, T., & Vaisman, N. (2016). Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. Nutrition & Metabolism, 13, p. 10. doi:10.1186/s12986-016-0070-5.
Niv E, et al. Randomized Clinical Study: Partially Hydrolyzed Guar Gum (PHGG) Versus Placebo in the Treatment of Patients With Irritable Bowel Syndrome. Nutr Metab (Lond). 2016;13:10. PubMed PMID: 26855665.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. AU - Niv,E, AU - Halak,A, AU - Tiommny,E, AU - Yanai,H, AU - Strul,H, AU - Naftali,T, AU - Vaisman,N, Y1 - 2016/02/06/ PY - 2015/11/14/received PY - 2016/01/27/accepted PY - 2016/2/9/entrez PY - 2016/2/9/pubmed PY - 2016/2/9/medline KW - Fibers KW - Irritable bowel syndrome (IBS) KW - Partially hydrolyzed guar gum (PHGG) KW - Prebiotics SP - 10 EP - 10 JF - Nutrition & metabolism JO - Nutr Metab (Lond) VL - 13 N2 - BACKGROUND: The treatment of Irritable bowel syndrome (IBS) is still challenging. Partially hydrolyzed guar gum (PHGG) is a known prebiotic fiber. To assess the effects of PHGG on clinical symptoms of IBS patients in a prospective randomized double blind placebo-controlled study. METHODS: Suitable IBS patients were recruited into an 18-week-long study (2 weeks of run-in, 12 weeks of treatment and 4 weeks of follow-up). They were blindly randomized to receive 6 gr of PHGG or placebo. Treatment efficacy was evaluated by the Francis Severity IBS score, the IBS quality-of-life scores and scored parameters of weekly journal of symptoms. Deltas of changes between the final and baseline scores were compared between two groups. RESULTS: Of 121 patients who underwent randomization, 108 patients (49 in the PHGG group and 59 in the placebo group) had all the data needed for intention-to-treat analysis. A 12-week administration of PHGG led to a significant improvement of journal bloating score in the PHGG group versus placebo (-4.1±13.4 versus -1.2±11.9, P=0.03), as well as in bloating+gasses score (-4.3±10.4 versus -1.12±10.5, P = 0.035). The effect lasted for at least 4 weeks after the last PHGG administration. PHGG had no effect on other journal reported IBS symptoms or on Severity and Quality of life scores. There were no significant side effects associated with PHGG ingestion. The rate of dropouts was significantly higher among patients in the placebo group compared with the PHGG group (49.15% versus 22.45%, respectively, P = 0.01). CONCLUSIONS: The results of this study support the administration of 6 g/day PHGG for IBS patients with bloating. TRIAL REGISTRATION: NCT01779765. SN - 1743-7075 UR - https://www.unboundmedicine.com/medline/citation/26855665/full_citation L2 - https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/s12986-016-0070-5 DB - PRIME DP - Unbound Medicine ER -